ALTEOGEN Inc. (KOSDAQ:196170)
South Korea · Delayed Price · Currency is KRW | Market Cap | 14.76T -37.8% |
| Revenue (ttm) | 254.01B +60.7% |
| Net Income | 191.70B +103.3% |
| EPS | 2,610.42 +109.9% |
| Shares Out | 69.63M |
| PE Ratio | 86.00 |
| Forward PE | 45.83 |
| Dividend | 285.38 (0.13%) |
| Ex-Dividend Date | Dec 29, 2025 |
| Volume | 125,983 |
| Open | 214,000 |
| Previous Close | 224,500 |
| Day's Range | 211,500 - 218,000 |
| 52-Week Range | 194,615 - 437,692 |
| Beta | 0.98 |
| Analysts | Buy |
| Price Target | 405,512.82 (+91.28%) |
| Est. Earnings | Nov 13, 2026 |
About ALTEOGEN
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the tre... [Read more]
Financial Performance
In 2025, ALTEOGEN's revenue was 215.86 billion, an increase of 109.87% compared to the previous year's 102.85 billion. Earnings were 141.67 billion, an increase of 127.57%.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for 196170 stock is "Buy." The 12-month stock price target is ₩405,513, which is an increase of 91.28% from the latest price.
News
Novartis Signs Up To $3.2B Hybrozyme Deal With Alteogen
(RTTNews) - Alteogen Inc. (196170.KQ), a South Korea-based biopharmaceutical company specializing in platform technologies, announced it has entered into an option and license agreement with Novartis ...
Novartis signs deal worth up to $3.2 billion for Alteogen's drug delivery technology
South Korea's Alteogen said on Wednesday it has signed a deal with Novartis worth up to $3.22 billion, giving the Swiss drugmaker access to its technology to make injectable versions of intravenous dr...
ALTEOGEN Q1 Net Income Declines
(RTTNews) - ALTEOGEN Inc. (196170.KQ) reported first quarter net income attributable to shareholders of the parent company of 71.7 billion Korean won, a 13.8% decrease compared to 83.2 billion won, a ...
Alteogen Stock Up On Upto $579 Mln Deal With Biogen For Hybrozyme-Based Subcutaneous Biologics
(RTTNews) - Shares of Alteogen Inc. (196170.KQ) gained around 6 percent on Thursday's trading in South Korea after the biopharma company announced that it has entered into an exclusive license agreeme...
ALTEOGEN Annual report: Q4 2025
ALTEOGEN has published its Q4 2025 annual report on March 22, 2026.
ALTEOGEN Quarterly report: Q3 2025
ALTEOGEN has published its Q3 2025 quarterly earnings report on November 13, 2025.
FDA Clears Merck's One-Minute Cancer Shot
The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co. Inc.’s (NYSE: MRK) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration i...